luxdegalutamide
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 3, 2025 (NCT07047118)
Timeline
Indications
Mechanism of action
- Androgen ReceptorDEGRADER
AR degrader
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(O[C@H]2C(C)(C)[C@H](NC(=O)c3ccc(N4CCC(CN5CCN(c6ccc(C(=O)N[C@H]7CCC(=O)NC7=O)c(F)c6)CC5)CC4)cc3)C2(C)C)ccc1C#N- Mol. weight
- 807.97 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314528 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07174063 | Phase 1 | Dec 26, 2025 | Novartis |
| NCT07206056 | Phase 1/Phase 2 (Phase 2) | Oct 15, 2025 | Novartis |
| NCT06991556 | Phase 2 | Jul 7, 2025 | Novartis |
| NCT07047118 | Phase 2 | Jul 3, 2025 | Novartis |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 4 | 4 | 2 | 2025 |
1 organizations
Page 1 / 1